在进行战略性评估和资本分配后，Pfizer表示，停止开发正处在中期临床阶段的丙肝药物filibuvir（PF-00868554）。该药物潜在的竞争对手来自Gilead和AbbVie的新药物。该公司表示，将继续优化公司的研发经费分配，优先开发下一代的创新药物和疫苗。
英文报道：
Biopharmaceutical company Pfizer has decided to discontinue the development of filibuvir, an experimental hepatitis C drug, following a strategic review and capital allocation.
The drug, which is in mid-stage clinical testing, is facing competition from new hepatitis C treatments developed by Gilead Sciences (GILD) and AbbVie (ABBV).
Pfizer spokeswoman Victoria Davis said, "We continue to prioritize our capital allocation to drive the next wave of innovative medicines and vaccines that bring benefit to patients and value to health care systems around the world."
The move shows the rapid changes in the hepatitis C treatment field.
In recent years, Pfizer's drug was on roughly equal footing with other similar drugs in development throughout the industry.
But over the couple of years, competitors including Gilead and AbbVie have revealed the development phase of drugs displaying impressive cure rates and other potential advantages over current standard treatment in clinical trials.
Based on that Pfizer has cut down its R&D spending and constricted the focus of its research efforts to other therapeutic areas, including neuroscience and oncology.
Filibuvir, which is also known as PF-00868554, is a non-nucleoside polymerase inhibitor, a class of drugs designed to help eradicate the hepatitis C virus. Hepatitis C is a liver-attacking virus estimated to infect up to 4 million Americans.
